Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Oral Oncol. 2013 Apr 25;49(8):733–737. doi: 10.1016/j.oraloncology.2013.03.447

Figure 1. Current p53-based therapeutics for HNSCC.

Figure 1

Adenoviral p53 gene therapy, Ad-p53, increases wildtype p53 levels in HNSCC cells. Onyx-015 selectively eliminates inactive p53 HNSCC cells. PRIMA-1 restores the ability of mutant p53 to bind to the p53 transcriptional response elements of target genes and CP-31398 stabilizes the DNA binding domain of mutant and wildtype p53. Nutlin-3 and RITA restore p53 function by blocking the p53-MDM2 interaction. CH1iB disrupts the HPV16 E6-p300 interaction to reactivate p53 in HPV16-positive HNSCC.